Escitalopram in treatment of antiandrogen-related mood disturbance in a patient with chronic schizophrenia and adenocarcinoma of the prostate.
Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC.
Lien-Cheng
LC
Kao
Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC.
Li-Fen
LF
Chen
Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC.
Yi-Chien
YC
Hsu
Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC; Department of Psychiatry, Tri-Service General Hospital, Song-Shan Branch, National Defense Medical Center, Taipei, Taiwan, ROC.
Wei-Chen
WC
Chuang
Department of Radiation Oncology, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taiwan, ROC.
Hsing-Lung
HL
Chao
Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC; Student Counseling Center, National Defense Medical Center, Taiwan, ROC.
Hsin-An
HA
Chang
Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC; Department of Psychiatry, Tri-Service General Hospital, Song-Shan Branch, National Defense Medical Center, Taipei, Taiwan, ROC.
Yu-Chen
YC
Kao
Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC.
Tien-Yu
TY
Chen
Department of Psychiatry, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC; Department of Radiation Oncology, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taiwan, ROC. Electronic address: stephenfaith@gmail.com.
Nian-Sheng
NS
Tzeng
D000230:Adenocarcinoma / Q000150:complications / Q000188:drug therapy*; D000726:Androgen Antagonists / Q000009:adverse effects*; D000813:Anilides / Q000009:adverse effects; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D015283:Citalopram / Q000627:therapeutic use*; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000139:chemically induced / Q000188:drug therapy*; D009570:Nitriles / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D012559:Schizophrenia / Q000150:complications*; D014105:Tosyl Compounds / Q000009:adverse effects
D000726:Androgen Antagonists; D000813:Anilides; D018687:Antidepressive Agents, Second-Generation; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D015283:Citalopram; C053541:bicalutamide; D016729:Leuprolide